Country: Canada
Language: English
Source: Health Canada
VEMURAFENIB
HOFFMANN-LA ROCHE LIMITED
L01EC01
VEMURAFENIB
240MG
TABLET
VEMURAFENIB 240MG
ORAL
56
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0153092001; AHFS:
APPROVED
2012-02-15
_ _ _ _ _Page 1 of 43_ _ _ _ _ PRODUCT MONOGRAPH Pr ZELBORAF ® vemurafenib Film-coated tablet, 240 mg Professed Standard Protein Kinase Inhibitor Hoffmann-La Roche Limited 7070 Mississauga Road Mississauga, Ontario, Canada L5N 5M8 Date of Revision: December 10, 2019 www.rochecanada.com Submission Control No: 231572 ZELBORAF ® is a registered trade-mark of F. Hoffmann-La Roche AG, used under license. Manufactured under license from Plexxikon Inc., a member of the Daiichi Sankyo group. © Copyright 2012-2019, Hoffmann-La Roche Limited _ _ _ _ _Page 2 of 43 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS .............................................................................. 4 ADVERSE REACTIONS .............................................................................................. 11 DRUG INTERACTIONS .............................................................................................. 19 DOSAGE AND ADMINISTRATION ........................................................................... 22 OVERDOSAGE ............................................................................................................ 24 ACTION AND CLINICAL PHARMACOLOGY .......................................................... 25 STORAGE AND STABILITY ..................................................................................... 27 SPECIAL HANDLING INSTRUCTIONS .................................................................... 27 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................... 27 PART II: SCIENTIFIC INFORMATION .................................................... Read the complete document